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Murine cytomegalovirus pools from various in vitro and in vivo sources were
compared for virulence in suckling mice in an effort to identify the conditions
which were necessary for the production of virulent and attenuated viruses. Virus
passaged in tracheal ring and salivary gland organ cultures, where virus is
produced primarily by epithelial cells, was even more attenuated than virus
passaged in mouse embryo fibroblasts. The attenuation observed after passage in
all three of these in vitro systems did not appear to be due to defective interfering
particles. We also found that virus produced in vivo in salivary glands became
attenuated with time after infection. Virus harvested from salivary glands 5 to 6
weeks after infection was highly attenuated compared with both salivary gland-
passaged virus harvested 2 to 3 weeks after infection and tissue culture-passaged
virus. The attenuation of salivary gland-passaged virus with time was reversed
when animals were treated with cyclophosphamide before the virus was har-
vested. A comparison of virus pools harvested from susceptible and resistant
mouse strains indicated that the mouse strain had little effect on the virulence of
the virus produced. When the various sources of virus tested in this study were
ranked in terms of the virulence of the virus produced, salivary glands in intact
mice either 2 to 3 weeks after infection or after cyclophosphamide treatment
produced the most virulent virus, followed by mouse embryo fibroblast cultures,
tracheal ring and salivary gland organ cultures, and, finally, salivary glands in
intact mice 5 to 6 weeks after infection.
Because cytomegalovirus is responsible for
congenital birth defects in an estimated 1 of
every 1,000 babies bom in the United States (6)
and because this virus poses a significant prob-
lem in patients who are immunosuppressed (4,
13, 23), considerable effort is being made to
develop a cytomegalovirus vaccine (3, 20, 25).
However, a number of reservations have been
expressed concerning the risks involved in ad-
ministering a live cytomegalovirus vaccine when
many basic questions concerning attenuation,
latency, reactivation, and oncogenic potential
remain unanswered (16,24). Many ofthese ques-
tions are difficult to investigate because human
cytomegalovirus does not infect laboratory ani-
mals. However, murine cytomegalovirus, a use-
ful laboratory model (29), has been used recently
to examine some of these questions (8, 11, 17).
In this study, murine cytomegalovirus pools de-
rived from various in vivo and in vitro sources
were compared for virulence in an effort to iden-
tify the conditions which were necessary for the
production of virulent and attenuated virus.
In 1971, Osborn and Walker (22) described the
rapid attenuation of murine cytomegalovirus
after passage through mouse embryo fibroblast
(MEF) cultures and the rapid restoration of
virulence by back passage of MEF-passaged vi-
rus in mice, with recovery of virus from salivary
glands. The features of the tissue culture envi-
ronment which effected such rapid attenuation
and the features of the salivary glands which
rapidly reversed the process were not identified.
At that time, MEF cultures provided the only
means of producing murine cytomegalovirus in
vitro. The demonstration that the epithelial lin-
ings of tracheal ring organ cultures (TROC) also
produce virus in vitro (14) has provided an en-
tirely different tissue culture environment for
virus production. We postulated that TROC
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might be an in vitro source of virulent virus and
that a comparison of MEF- and TROC-pro-
duced virus pools might help identify the tissue
culture conditions necessary for attenuation.
Similarly, a comparison of the virulence prop-
erties of virus pools from various in vivo sources
might help identify the features of those envi-
ronments which are responsible for virulence.
Since the original description of virulence and
attenuation, resistant and susceptible strains of
mice have been described (1, 19, 28), with no
indication of the virulence properties of the virus
produced by such mice. Other studies have dealt
with reactivation of latent virus by various im-
munosuppressive therapies (12, 15). Included
among these studies is a report in which mice
vaccinated with attenuated virus produced vir-
ulent virus after immunosuppression (11).
This study was undertaken to answer the fol-
lowing questions. How do the virulence proper-
ties of virus passaged in vitro in culture systems
other than embryo fibroblasts compare with the
virulence properties of mouse salivary gland-
and MEF-passaged virus? How do the virulence
properties of virus pools produced in different
strains of mice compare? Is the virus produced
in salivary glands of chronically infected mice as
virulent as that produced in acutely infected
mice? And what impact does immunosuppres-
sive treatment have on the virulence of the
virus?
MATERLALS AND METHODS
Mice. Outbred CD-1 mice were obtained from
Charles River Farms, Wilmington, Mass. Pregnant
mice for MEF cultures and for production of litters for
assessing the virulence properties of virus pools were
shipped after 15 days of gestation. CD-1 mice were
shipped when they were 30 days old and were used
within a few weeks of arrival for producing virus pools
and organ cultures. C3H/Hej mice were obtained when
they were 4 to 6 weeks old from Jackson Laboratory,
Bar Harbor, Maine, and were used shortly thereafter
for producing virus pools.
Tissue and organ cultures. Primary and second-
ary MEF cultures were prepared from CD-1 mouse
embryos (16 to 18 days of gestation) by previously
described methods (27). TROC containing six to eight
individual tracheal rings, each with a single cartilage,
were prepared as described by Nedrud et al. (19).
Salivary gland organ cultures (SGOC) were prepared
by asceptically removing CD-1 mouse salivary glands,
mincing these glands into small pieces (approximately
1 mm3), and placing them on grids (type 3014; Falcon
Plastics, Oxnard, Calif.) in organ culture dishes (type
3037; Falcon Plastics). The center well of each dish
was filled with basal Eagle medium containing Earle
salts (GIBCO Laboratories, Grand Island, N.Y.), 2%
fetal calf serum, 200 U of penicillin per ml, and 200 jg
of streptomycin per ml. Cultures were incubated at
37°C in an atmosphere containing 5% CO2.
Viru8. The Smith strain of murine cytomegalovirus
was obtained from the American Type Culture Asso-
ciation, Rockville, Md., at tissue passage 12. Subse-
quently, it was passed once in MEF and twice in mouse
salivary glands to produce the first wild-type stock
virus. Passage of virus through mouse salivary glands
was accomplished by inoculating adult mice intraper-
itoneally with 105 plaque-forming units (PFU) of mu-
rine cytomegalovirus and then sacrificing these mice
either 2 to 3 or 5 to 6 weeks after infection. In some
cases, mice were given intraperitoneal inoculations of
150 mg of cyclophosphamide (Cytoxan; Mead Labo-
ratories, Evansville, Ind.) per kg 9 and 4 days before
they were sacrificed at 5 weeks. Salivary glands were
removed, pooled, ground with a mortar and pestle to
a 10% (wt/vol) extract in maintenance medium (me-
dium 199 in Hanks buffer containing 3% fetal calf
serum, 200 U of penicillin per ml, and 200 ,ug of
streptomycin per ml), and clarified by low-speed cen-
trifugation. The salivary gland-passaged virus har-
vested 2 to 3 weeks postinfection is referred to below
as wild-type virus. All virus pools were stored in small
portions with 10% dimethyl sulfoxide at -70°C. Figure
1 shows the histories of the passages through MEF,
TROC, and SGOC to produce the virus pools used in
this study. To obtain MEF-passaged murine cytomeg-
alovirus pools, cells were infected at different multi-
plicities in 3-ml volumes in 150-cm2 tissue culture
flasks. After 2 h of stationary adsorption at 37°C, an
additional 10 ml of maintenance medium was added
to each flask. The cultures were incubated for 4 to 5
days until 95% cytopathic effects were observed, and
then the culture fluids were clarified by centrifugation
and stored. TROC and SGOC were infected as previ-
ously described. Briefly, cultures were inoculated with
0.1 to 0.2 ml of undiluted seed virus. After adsorption
for 2 h at 37°C, these cultures were rinsed and fed with
fresh medium. Culture fluids were collected 10 to 16
days later, clarified, and stored. The infectivity titers
of all virus pools were determined by plaque assays on
MEF, as previously described (19).
Comparison of virulence properties of virus
pools. We used two methods to compare the virulence
properties of various virus pools in 5- to 6-day-old
suckling mice. Animals from five to seven litters were
pooled, randomly distributed among the mothers, and
inoculated intraperitoneally with 0.05-ml volumes of
serial twofold dilutions of a virus pool; these animals
were observed for mortality for 4 weeks. This process
was repeated several times, and the dose which pro-
duced 50% mortality (50% lethal dose [LD5o]) was
calculated by probit analysis (5). Alternatively, ran-
domized litters of mice were inoculated with a stand-
ard number of PFUs of virus from various sources,
and the cumulative percent mortalities obtained with
virus pools from different sources were compared on
progressive days postinfection. The differences in the
mortalities produced by the different virus pools were
analyzed by the chi-square test. In some cases, passage
3 MEF- or TROC-produced virus at a final concentra-
tion of 4 x 103 PFU/mouse was mixed with serial
dilutions of wild-type virus before inoculation into
suckling mice, and the mortalities obtained after 4
weeks were compared with the mortalities obtained
after mice were inoculated with the same dilutions of
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FIG. 1. Histories of virus pools passaged in vitro and used in this study. Asterisks indicate the virus pools
actually used. m, Multiplicity of infection. Parentheses indicate the titers of the virus pools at each passage
level (in PFUper milliliter).
wild-type virus without MEF- or TROC-produced vi-
rus. Animals inoculated with normal salivary gland
homogenate or maintenance medium containing 10%
dimethyl sulfoxide in the absence of virus showed no
adverse effects.
RESULTS
Attenuation of virus by in vitro tissue
passage. Figure 2A compares the percent mor-
talities in suckling mice after inoculation with 8
x 103 PFU of wild-type virus and after inocula-
tion with the same dose of virus passaged 1 to 4
times in MEF. When these results were analyzed
by the chi-square test, the percent mortality due
to the wild-type virus was significantly different
from the percent mortalities due to all MEF-
passaged viruses (P < 0.00001), and the percent
mortality due to virus passaged once in MEF
was significantly different from the percent mor-
talities due to virus passaged 2 to 4 times in
MEF (P = 0.03). Hence, the MEF passage 1
virus was intermediate in virulence between
wild-type virus and virus pools from subsequent
MEF passages, which exhibited the same degree
ofvirulence (P= 0.34). Figure 2B shows a similar
effect after suckling mice were inoculated with
104 PFU of wild-type virus and TROC-passaged
virus. However, in this case no virus of inter-
mediate virulence was observed. The difference
in percent mortalities between wild-type virus
and TROC-passaged virus was highly significant
(P < 0.00001), but there was no difference in the
attenuation of passages 1 through 3 (P = 0.54).
Mice infected with all attenuated virus showed
not only a decrease in mortality but also a delay
in the onset of mortality.
Sirnilar results are shown in Table 1, which
gives the LD50 values for the virus pools pro-
duced in SGOC, as well as for the virus pools
produced in TROC and MEF and for wild-type
virus. Again, virus passaged once in MEF ap-
peared to have intermediate virulence, whereas
virus passaged in TROC and SGOC was atten-
uated after one passage. The LD50 values ofvirus
pools from MEF passages 2 through 4 were
about 10-fold higher than the LD50 for wild-type
virus. Virus yields made it impossible to deter-
mine the LDso values for SGOC- and TROC-
passaged virus beyond one passage; however,
the data suggest that these values would be
higher than the LD50 values for virus pools from
comparable passages in MEF.
Role of defective interfering particles in
attenuation. Table 1 also shows that similar
results were obtained with virus passages 1 and
2 in MEF regardless of whether the virus was
passaged at a high or a low multiplicity. There
was no indication of interference in pools pas-
saged at a high multiplicity of infection.
Figure 1 shows the passage histories of the
virus pools produced in vitro for this study. With
the exception ofthe last series, all MEF passages
were made at a low multiplicity of infection,
which tends to prevent the accumulation of de-
fective virus. Because the exact number of cells
in the TROC and SGOC could not be deter-
mined easily, it was not possible to determine
the multiplicity of infection for passages in these
cultures. There was no evidence for the accu-
mulation of defective interfering particles. A de-
cline in virus titer after passage in TROC did
not occur, and there was a slight but gradual
increase in virus titer during passage in MEF.
Thus, pools of virus which were less able to kill
suckling mice than wild-type virus were as pro-
ductive as or more productive than wild-type
virus when they were inoculated into MEF or
TROC. Also, the titers obtained at a high mul-
tiplicity of infection in MEF were, if anything,
greater than those obtained for the same passage
at a low multiplicity of infection.
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interfering particles accounted for the attenua-
tion of many viruses during tissue passage, fur-
ther studies were performed to determine
whether defective interfering particles contrib-
uted to the attenuation observed in this study.
Table 2 shows the results obtained when virus
passaged 3 times in MEF or TROC was mixed
with varying dilutions of wild-type virus before
mice were inoculated and the percent mortalities
obtained compared with those obtained when
the same dilutions of wild-type virus were inoc-
ulated alone. No significant differences in mor-
tality were observed when TROC-passaged virus
was mixed with virulent virus; hence, nothing in
the TROC-passaged virus inhibited the viru-
lence of wild-type virus. The same was true for
two of the three MEF-passaged mixtures. A
statistically significant difference was obtained
when MEF-passaged virus was mixed with the
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ever, this difference was probably not related to
the presence of defective particles since such
particles present in a constant dose of MEF-
passaged virus would be expected to have the
greatest inhibitory effect on lower doses of vir-
ulent virus and the least effect on higher doses.
Attenuation of virus in vivo. In further
attempts to improve our understanding of the
conditions necessary to produce virulent and
attenuated virus, virus pools from various
sources of mouse salivary gland virus were com-
pared for virulence. Table 3 shows the LD50
values of virus pools produced in vivo in salivary
glands of resistant (C3H) and susceptible (CD-1)
mouse strains and also compares the LD50 values
obtained for virus pools harvested 2 to 3 and 6
weeks postinfection. The data indicate no differ-
ence in the LD50 values for virus pools produced
in C3H and CD-1 mice; however, the time at
which the virus was harvested significantly af-
DAYS POST INFECTION DAYS POST INFECTION
FIG. 2. Mortality in suckling mice. (A) Mice inoculated with wild-type murine cytomegalovirus and mice
inoculated with virus from MEF passages 1 through 4. All doses were 8 x 103 PFU. Symbols: 0, virus from
MEFpassage 1 (12 of 22 mice died); A, virus from MEF passage 2 (11 of 51 mice died); E, virus from MEF
passage 3 (10 of 28 mice died); *, virus from MEFpassage 4 (4 of 19 mice died); U, wild-type virus (60 of 64
mice died). (B) Mice inoculated with wild-type virus (8 x 103 PFU) and mice inoculated with virus from TROC
passages 1 through 3 (1 x 104 PFU). Symbols: 0, virus from TROCpassage 1 (5 of30 mice died); A, virus from
TROCpassage 2 (9 of44 mice died); O, virus from TROC passage 3 (2 of21 mice died); U, wild-type virus (60
of 64 mice died). When the results were analyzed by the chi-square test, the mortality due to wild-type virus
was significantly different from the mortalities due to all MEF- and TROC-passaged virus (P < 0.00001).
Also, the mortality due to virus from MEF passage I was significantly different from the mortalities due to
virus from MEF passages 2, and 4 (P - 0.03); however, there was no difference in the mortalities due to virus
from MEFpassages 2, 3, and 4 (P = 0.34) or in those due to virus from TROCpassage 1, 2, and 3 (P = 0.54).
2 4 6 8 10 12 14 16 18 20 22
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TABLE 1. Comparison ofLD50 of virus pools derived from various in vitro sources with wild-type virus LD5o
LD5o (PFU) of virus derived from:b
Passage MOja
MEF TROC SGOC
0 (wild type) 1.7 x 103 1.7 x 103 1.7 x 103
(1.2 x 103-2.2 x 103) (1.2 x 103-2.2 x 103) (1.2 x 103-2.2 x 103)
1 Low 7.9 x 103 1.6 X 104C >1.0X 104d
(5.6 x 1031-.1 x 104)
1 High 4.1 x 103 NDe ND
(2.0 x 103-7.1 x 103)
2 Low 2.1 x 10' >2.0 x 104f ND
(1.4 x 104-2.7 x 104)
2 High 2.3 x 10 ND ND
(1.3 x 104-5.6 x 104)
3 Low 1.5 x 104 >2.0 x 1049 ND
(6.5 x 103-2.3 x 104)
4 Low 3.5 x 104 ND ND
(2.7 x 104-4.4 x 104)
a MOI, Multiplicity of infection.
b LD5o values were calculated by using probit analysis. The numbers in parentheses are the 90% confidence
limits. Each LD5o represents a single virus pool.
'There was insufficient virus to get a good value by probit analysis. The LD50 was determined roughly from
data showing 6 of 10 mice dead at a dose of 2 x 104 PFU and 2 of 21 mice dead at a dose of 1 x 10' PFU.
d Highest dose available for inoculation. The percent mortality at this dose was 19% (4 of 21 mice died).
'ND, Not done.
f Highest dose available for inoculation. The percent mortality at this dose was 27% (3 of 11 mice died).
B Highest dose available for inoculation. The percent mortality at this dose was 45% (13 of 29 mice died).
TABLE 2. Effect ofmixing virulent and attenuated viruses
Expt 1 Expt 2
Dose of viru-
lent virus % Mortality with % Mortality with % Mortality with % Mortality with
(PFU) virulent virus alone MEF-passged vi p virulent virus TROC-pasaged pb
rus alone virus
8 x 103 100 (22/22)C 71 (15/21) 0.01 NDd ND
4 x 103 83 (19/23) 77 (17/22) 0.65 70 (7/10) 80 (8/10) 0.60
2 x 103 76 (16/21) 67 (14/21) 0.49 60 (6/10) 82 (9/11) 0.26
1 X 103 ND ND 45 (5/11) 36 (4/11) 0.66
a Virus from MEF passage 3 or TROC passage 3 at a final dose of 4 x 103 PFU was mixed with varying
dilutions of virulent virus before inoculation into suckling mice. The resulting percent mortalities were compared
with the percent mortalities of mice which received the same dilutions of virulent virus alone.
b Differences were analyzed by the chi-square test.C Numbers in parentheses are number dead/number inoculated.
d ND, Not done.
fected virulence. Whereas 8 x 103 PFU of virus
harvested 2 to 3 weeks postinfection killed 95%
of the inoculated mice (Fig. 2), 6.4 x 104 PFU of
virus harvested 6 weeks postinfection did not
kill any mice (Table 3). The LD50 values for 6-
week virus could not be calculated due to virus
yields, but they certainly more than exceeded a
60-fold increase over virus harvested 2 to 3 weeks
after infection.
Reversal of in vivo attenuation by im-
munosuppressive treatment. Figure 3 shows
that the attenuation which occurred with time
in mouse salivary glands could be reversed by
treating mice with 150 mg of cyclophosphamide
per kg 9 and 4 days before virus was harvested
at 5 weeks postinfection. Whereas 2 x 105 PFU
of salivary gland-passaged virus from untreated
mice killed only 30% of the suckling mice inoc-
ulated, the same dose of virus from cyclophos-
phamide-treated animals killed 100%, a signifi-
cant difference (P< 0.00001). The LD5o for virus
harvested after cyclophosphamide treatment
was 2.1 x 103 PFU/mouse (90% confidence lim-
its, 1.8 x 103 to 2.6 x 103 PFU/mouse), a value
comparable to the values obtained for salivary
gland-passaged virus pools harvested 2 to 3
weeks postinfection (Table 3). In contrast, the
LD5o for virus harvested from untreated mice at
5 weeks was more than 2 x 105 PFU/mouse (the
highest dose available for inoculation).
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A similar reversal in attenuation was observed
when mice were treated simultaneously with
goat anti-mouse lymphocyte serum (twice
weekly for 3 weeks) and 125 mg of hydrocorti-
TABLE 3. Virulence of virus pools produced in vivo
in salivary glands
Time between
Mouse strain infection and LD50 (PFU)a
harvest
CD-1 14 days 1.7 X 103
(1.2 x 103-2.2 x 103)
CD-1 17 days 8.2 x 102
(4.7 x 102-1.1 x 103)
C3H 19 days 1.5 x 103
(6.3 x 102-2.2 x 103)
CD-1 6 weeks >6.4 x 104b
C3H 6 weeks >1.2 x 105c
a LD50 values were calculated by using probit anal-
ysis. The numbers in parentheses are the 95% confi-
dence limits. Each LD50 represents one virus pool.
b Highest dose available for inoculation. At this dose
none of 22 mice inoculated died.
c Highest dose available for inoculation. At this dose
none of 19 mice inoculated died.
sone per kg (three times weekly for 2 weeks)
immediately before salivary gland-passaged vi-
rus was harvested at 5 weeks postinfection.
DISCUSSION
This study demonstrated that in vitro passage
of murine cytomegalovirus in TROC and SGOC
resulted in even more rapid attenuation than
passage in MEF. The virus pools produced in
vivo in the salivary glands of susceptible and
resistant strains of mice were equally virulent
for outbred suckling mice, suggesting that the
mouse strain does not play an important role in
determining the virulence of the virus produced.
However, the time at which the virus is har-
vested from the salivary glands appears to be
critical, since salivary gland-passaged virus har-
vested 5 to 6 weeks after infection was highly
attenuated compared with salivary gland-pas-
saged virus harvested 2 to 3 weeks after infec-
tion. When chronically infected mice were
treated with cyclophosphamide before sacrifice,
the resulting virus was as virulent as that ob-
tained earlier in infection.
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DAYS POST INFECTION (2 x 105 ph.)
FIG. 3. Two pools of virus were derived from mouse salivary glands 5 weeks after infection. Onepool came
from mice treated with 150 mg of cyclophosphamide per kg 4 and 9 days before harvest; the other pool came
from untreated mice. Suckling mice were each inoculated with 2 x 105 PFU from one of these pools, and the
percent mortalities for the two pools were compared. Symbols: U, virus derived from cyclophosphamide-
treated mice (19 of 19 inoculated mice died); 0, virus from control mice (12 of 36 inoculated mice died).
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of virus in MEF were similar to those reported
by Osborn and Walker (22). Not only did MEF
passage result in decreased mortality, but the
length of time between inoculation and death
was extended. Since salivary glands are the
sources of virulent virus in intact mice and since
much of the virus produced in these glands
comes from epithelial cells (18), one might ex-
pect that an in vitro infection of epithelial cells
would produce more virulent virus than the virus
produced in fibroblasts. This was not observed.
Fluorescent antibody and histological studies
have suggested that epithelial cells are the main
sources of virus in TROC and SGOC (14; unpub-
lished data) but virus produced in these cultures
appeared to be less virulent for suckling mice
than virus produced in fibroblasts in vitro. Also,
previous studies (19) indicated that TROC from
resistant mouse strains were much less efficient
virus producers and showed fewer cytopathic
effects than TROC from susceptible mouse
strains. Although there seems to be a direct
correlation between mouse strain and produc-
tion of virus in TROC, mouse strain does not
appear to influence the production of virulent or
attenuated virus.
In all of the cell types tested in vitro atten-
uation did not appear to be due to defective
interfering particles, at least as they are typically
described (9). Accumulations of such particles
during passage would interfere with in vitro as
well as in vivo production of virus and would
cause in vitro-passaged virus to interfere with
the virulence of wild-type virus when the two
were mixed. Neither of these phenomena was
observed in this study. We cannot eliminate the
possibility that the "multicapsid virions" de-
scribed by Hudson et al. (10), which appear to
be absent from infected salivary gland homoge-
nates but to be prevalent in infected MEF su-
pernatants, are somehow related to attenuation.
Although these multicapsid virions may produce
plaques and infectious virus in tissue culture
with an efficiency similar to the efficiency of
single capsid virions, they may be handled dif-
ferently by intact animals.
In mice, the source of virulent virus appears
to be limited to the salivary glands. Other work-
ers have found that virus harvested during acute
stages of infection from livers, spleens, and kid-
neys are more attenuated for suckling mice than
MEF-passaged virus (2; J. E. Osborn, personal
communication). Furthermore, the results de-
scribed here indicate that salivary gland produc-
tion of virulent virus is limited to the first few
weeks of infection. By 5 weeks after infection,
salivary gland-passaged virus is also more atten-
uated than MEF-passaged virus. Virulence and
attenuation are relative terms which compare
the abilities of two or more strains of virus to
produce disease. When MEF-passaged virus is
compared only with salivary gland-passaged vi-
rus harvested 2 to 3 weeks after infection or from
mice treated with cyclophosphamide, the MEF-
passaged virus is naturally referred to as atten-
uated. However, it is clear from this discussion
that the most attenuated virus is derived from
livers, spleens, and kidneys of intact mice and
from salivary glands late after infection. Com-
pared with virus produced in these organs and
in SGOC and TROC, MEF-passaged virus is
virulent.
The modulation of salivary gland-passaged
virus from virulent to attenuated during the
course of infection may be related to the modu-
lation of the immune response, which is de-
pressed during the acute phase of infection (21,
26) but subsequently recovers and is even en-
hanced in the chronic stage of infection (30; H.
H. Balfour, D. M. Mattsson, and R. J. Howard,
Clin. Res. 26:717A, 1978). The fact that cyclo-
phosphamide treatment and anti-mouse lym-
phocyte serum-cortisone treatment, both of
which depress immune responses (7, 12), caused
chronically infected mice to produce virulent
virus suggests that host immune responses do
somehow affect the virulence of the virus pro-
duced. Alternatively, the effects of cyclophos-
phamide and cortisone could be unrelated to
their immunosuppressive effects. Mims and
Gould (18) have suggested that there are "sexual
factors" present in the salivary glands, which
affect the virulence ofthe virus produced. Cyclo-
phosphamide or cortisone or both could exert an
effect by altering these factors.
Whatever the reason for the enhanced viru-
lence of virus after immunosuppressive treat-
ment, it is obviously clinically significant for
several reasons. First, in terms of justifying a
vaccine, apparently attenuated vaccine virus
may revert to virulence in immunocompromised
hosts, causing adverse effects in some of the very
people that the vaccine is meant to protect.
Second, immunosuppressed patients who are
seropositive for cytomegalovirus may shed virus
having increased virulence and therefore may be
more likely to infect seronegative contacts. In
terms of managing immunosuppressed patients,
it might be beneficial to separate patients who
are seronegative from those who are not.
In this paper we raise several questions which
have importance relative to the current interest
in cytomegalovirus vaccines. The observations
that passage of virus in tissue culture produces
more virulent virus than passage in the spleens
and livers of acutely infected animals and that
INFECT. IMMUN.
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chronically infected animals shed more virulent
virus when they are immunosuppressed point
out several potential pitfalls to successful utili-
zation of a vaccine.
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